http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 06:38:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/AGC+Inc+%285201%3AJP%29+%28ASGLY%29+PT+Raised+to+JPY7%2C500+at+JPMorgan/26650089.html JPMorgan analyst Mio Shikanai raised the price target on AGC Inc (5201:JP) (OTC: ASGLY) to JPY7,500.00 (from JPY5,200.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/AGC+Inc+%285201%3AJP%29+%28ASGLY%29+PT+Raised+to+JPY7%2C500+at+JPMorgan/26650089.html Tue, 16 Jun 2026 06:38:40 -0400 ASGLY http://www.streetinsider.com/Intl+Ratings/AGC+Inc+%285201%3AJP%29+%28ASGLY%29+PT+Raised+to+JPY7%2C500+at+JPMorgan/26650089.html JPMorgan analyst Mio Shikanai raised the price target on AGC Inc (5201:JP) (OTC: ASGLY) to JPY7,500.00 (from JPY5,200.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/AGC+Inc+%285201%3AJP%29+%28ASGLY%29+PT+Raised+to+JPY7%2C500+at+JPMorgan/26650089.html Tue, 16 Jun 2026 06:38:40 -0400 ASGLY http://www.streetinsider.com/Analyst+PT+Change/AGC+Inc+%285201%3AJP%29+%28ASGLY%29+PT+Raised+to+JPY7%2C500+at+JPMorgan/26650089.html JPMorgan analyst Mio Shikanai raised the price target on AGC Inc (5201:JP) (OTC: ASGLY) to JPY7,500.00 (from JPY5,200.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/AGC+Inc+%285201%3AJP%29+%28ASGLY%29+PT+Raised+to+JPY7%2C500+at+JPMorgan/26650089.html Tue, 16 Jun 2026 06:38:40 -0400 ASGLY http://www.streetinsider.com/Analyst+PT+Change/AGC+Inc+%285201%3AJP%29+%28ASGLY%29+PT+Raised+to+JPY7%2C500+at+JPMorgan/26650089.html JPMorgan analyst Mio Shikanai raised the price target on AGC Inc (5201:JP) (OTC: ASGLY) to JPY7,500.00 (from JPY5,200.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/AGC+Inc+%285201%3AJP%29+%28ASGLY%29+PT+Raised+to+JPY7%2C500+at+JPMorgan/26650089.html Tue, 16 Jun 2026 06:38:40 -0400 ASGLY http://www.streetinsider.com/Press+Releases/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html <p class="bwalignc"> <b>－Fluorine Content attributed as 100% “Recycled Circular Fluorite” Based on Mass Balance Credit Allocation－</b> </p> <p> TOKYO--(BUSINESS WIRE)-- AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification*1 based on UL 2809*2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach*3, 100%*4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the http://www.streetinsider.com/Press+Releases/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html Thu, 28 May 2026 22:00:00 -0400 5201 AGC ASGLY O.05105704 http://www.streetinsider.com/Press+Releases/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html <p class="bwalignc"> <b>－Fluorine Content attributed as 100% “Recycled Circular Fluorite” Based on Mass Balance Credit Allocation－</b> </p> <p> TOKYO--(BUSINESS WIRE)-- AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification*1 based on UL 2809*2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach*3, 100%*4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the http://www.streetinsider.com/Press+Releases/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html Thu, 28 May 2026 22:00:00 -0400 5201 AGC ASGLY O.05105704 http://www.streetinsider.com/Press+Releases/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html <p class="bwalignc"> <b>－Fluorine Content attributed as 100% “Recycled Circular Fluorite” Based on Mass Balance Credit Allocation－</b> </p> <p> TOKYO--(BUSINESS WIRE)-- AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification*1 based on UL 2809*2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach*3, 100%*4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the http://www.streetinsider.com/Press+Releases/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html Thu, 28 May 2026 22:00:00 -0400 5201 AGC ASGLY O.05105704 http://www.streetinsider.com/Press+Releases/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html <p class="bwalignc"> <b>－Fluorine Content attributed as 100% “Recycled Circular Fluorite” Based on Mass Balance Credit Allocation－</b> </p> <p> TOKYO--(BUSINESS WIRE)-- AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification*1 based on UL 2809*2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach*3, 100%*4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the http://www.streetinsider.com/Press+Releases/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html Thu, 28 May 2026 22:00:00 -0400 5201 AGC ASGLY O.05105704 http://www.streetinsider.com/Business+Wire/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html <p class="bwalignc"> <b>－Fluorine Content attributed as 100% “Recycled Circular Fluorite” Based on Mass Balance Credit Allocation－</b> </p> <p> TOKYO--(BUSINESS WIRE)-- AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification*1 based on UL 2809*2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach*3, 100%*4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the http://www.streetinsider.com/Business+Wire/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html Thu, 28 May 2026 22:00:00 -0400 5201 AGC ASGLY O.05105704 http://www.streetinsider.com/Business+Wire/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html <p class="bwalignc"> <b>－Fluorine Content attributed as 100% “Recycled Circular Fluorite” Based on Mass Balance Credit Allocation－</b> </p> <p> TOKYO--(BUSINESS WIRE)-- AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification*1 based on UL 2809*2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach*3, 100%*4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the http://www.streetinsider.com/Business+Wire/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html Thu, 28 May 2026 22:00:00 -0400 5201 AGC ASGLY O.05105704 http://www.streetinsider.com/Business+Wire/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html <p class="bwalignc"> <b>－Fluorine Content attributed as 100% “Recycled Circular Fluorite” Based on Mass Balance Credit Allocation－</b> </p> <p> TOKYO--(BUSINESS WIRE)-- AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification*1 based on UL 2809*2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach*3, 100%*4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the http://www.streetinsider.com/Business+Wire/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html Thu, 28 May 2026 22:00:00 -0400 5201 AGC ASGLY O.05105704 http://www.streetinsider.com/Business+Wire/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html <p class="bwalignc"> <b>－Fluorine Content attributed as 100% “Recycled Circular Fluorite” Based on Mass Balance Credit Allocation－</b> </p> <p> TOKYO--(BUSINESS WIRE)-- AGC (TOKYO:5201) (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai) a world-leading manufacturer of glass, chemicals and other high-tech materials, announces that it has completed a third-party verification*1 based on UL 2809*2 in May 2026 for the fluorine raw materials used in AFLAS™ FFKM. The third-party verification confirmed that, for allocation of recycled content under the mass balance approach*3, 100%*4 of the fluorine content allocated to AFLAS™ FFKM is attributed to recycled fluorite (hereinafter “Recycled Circular Fluorite”). This initiative is among the http://www.streetinsider.com/Business+Wire/AGC+Completes+Third-Party+Verification+Under+UL+2809+for+Fluorine+Raw+Materials+Used+in+AFLAS%E2%84%A2+FFKM/26569522.html Thu, 28 May 2026 22:00:00 -0400 5201 AGC ASGLY O.05105704 http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Press+Releases/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Globe+Newswire/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Globe+Newswire/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Globe+Newswire/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Globe+Newswire/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Globe+Newswire/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Globe+Newswire/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785 http://www.streetinsider.com/Globe+Newswire/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html <p align="left">HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation.</p> <p>“Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need,” said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. “We value their collaborative http://www.streetinsider.com/Globe+Newswire/AGC+Biologics+to+Manufacture+Teikoku+Seiyaku%26apos%3Bs+rhMMP-7+Drug+Substance/26544555.html Mon, 25 May 2026 20:00:00 -0400 5201 A.10912314 A.20966727 A.50216137 ASGLY O.00167585 O.05105704 O.38707971 O.40439785